Skip to main content

Advertisement

SpringerLink
Log in

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

  • Research Articles
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

The aim of this study was to investigate whether X-ray repair cross-complementing group 3 (XRCC3) and xeroderma pigmentosum group D (XPD) single nucleotide polymorphism (SNP) affects the outcome of platinum-based chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients.

Material and methods

From September 2005 to June 2009, 355 advanced-stage NSCLC patients were accrued to compare the SNP variants with the outcome of platinum-based chemotherapy. TaqMan RT-PCR was used to evaluate the SNPs of the XRCC3 codon241 (Thr/Met) and XPD codon751 (Lys/Gln) DNA repair genes.

Results

There was a lack of association between the studied SNPs and the response rate, progression-free survival or overall survival (OS) in the whole population. However, subgroup analysis revealed that XRCC3 241 Thr/Met or Met/Met allele was associated with marginally significantly longer OS than XRCC3 Thr/Thr allele (19.0 m vs. 12.5 m, p=0.081) in the patients treated with gemcitabine/cisplatin or carboplatin (GP/GC) while it was correlated with a significantly shorter OS in the patients treated with non GP/GC (9.3 m vs. 16 m, p=0.003). XPD751 Lys/Lys had an association with statistical significantly longer OS than XPD751 Lys/Gln or Gln/Gln in the subgroup of elderly patients (14.10 m vs. 10 m, p=0.019) and patients with non-adenocarcinoma (12.6 m vs. 9 m, p=0.042).

Conclusions

XRCC3 Thr241Met played an opposite role in predicting prognosis of chemotherapy in NSCLC patients according to the first-line regimens. XPD 751 Lys/Lys might be a better prognostic marker of elderly or noncarcinoma NSCLC subgroup treated with platinum-based chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  2. Tahara E, Yasui W, Ito H et al (2009) Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities’ Consortium International Symposium. Jpn J Clin Oncol 40:702–708

    Article  Google Scholar 

  3. Grønberg BH, Bremnes RM, Fløtten O et al (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-smallcell lung cancer. J Clin Oncol 27:3217–3224

    Article  PubMed  Google Scholar 

  4. Gossage L, Madhusudan S (2007) Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 11:361–380

    PubMed  CAS  Google Scholar 

  5. Matullo G, Palli D, Peluso M et al (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22:1437–1445

    Article  PubMed  CAS  Google Scholar 

  6. Qiao Y, Spitz MR, Shen H et al (2002) Modulation of repair of ultraviolet damage in the host cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 23:295–299

    Article  PubMed  CAS  Google Scholar 

  7. Zhou C, Ren S, Zhou S et al (2010) Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 40:954–960

    Article  PubMed  Google Scholar 

  8. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437:1299–1320

    Article  Google Scholar 

  9. Matullo G, Guarrera S, Carturan S et al (2001) DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 92:562–567

    Article  PubMed  CAS  Google Scholar 

  10. de las Peñas R, Sanchez-Ronco M, Alberola V et al (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17:668–675

    Article  PubMed  Google Scholar 

  11. Bosken CH, Wei Q, Amos CI et al (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94:1091–1099

    Article  PubMed  Google Scholar 

  12. Zhang Zl, Zhou CC, Zhang J et al (2007) Relationship between polymorphisms of DNA repair gene XRCC3 and susceptibility to lung cancer. Chin J Tuberculosis Resp Dis 30:1215–1220

    Google Scholar 

  13. Schöllnberger H, Manuguerra M, Bijwaard H et al (2006) Analysis of epidemiological cohort data on smoking effects and lung cancer with a multistage cancer model. Carcinogenesis 27:1432–1444

    Article  PubMed  Google Scholar 

  14. Zienolddiny S, Campa D, Lind H et al (2006) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27:560–567

    Article  PubMed  CAS  Google Scholar 

  15. Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194–203

    Article  PubMed  CAS  Google Scholar 

  16. Ryu JS, Hong YC, Han HS et al (2004): Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44:311–316

    Article  PubMed  Google Scholar 

  17. Rosell-Costa R, Alberola V, Camps C et al (2006) Clinical outcome of gemcitabine (gem)/cisplatin (cis)-vs docetaxel (doc)/cis-treated stage IV non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age. J Clin Oncol 24:7055

    Google Scholar 

  18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216

    CAS  Google Scholar 

  19. Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594–2601

    Article  PubMed  CAS  Google Scholar 

  20. Zhou W, Gurubhagavatula S, Liu G et al (2004) Excision repair ross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939–4943

    Article  PubMed  CAS  Google Scholar 

  21. Chen S, Tang D, Xue K et al (2002) DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 23:1321–1325

    Article  PubMed  Google Scholar 

  22. Aloyz R, Xu ZY, Bello V et al (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62:5457–5462

    PubMed  CAS  Google Scholar 

  23. Liu L, Yuan P, Wu C et al (2010) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73:110–115

    Article  PubMed  Google Scholar 

  24. Yao CY, Huang XE, Li C et al (2009) Lack of in-fluence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 10:859–864

    PubMed  Google Scholar 

  25. Tibaldi C, Giovannetti E, Vasile E et al (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797–1803

    Article  PubMed  CAS  Google Scholar 

  26. Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344–354

    PubMed  CAS  Google Scholar 

  27. Park DJ, Stoehlmacher J, Zhang W et al (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654–8658

    PubMed  CAS  Google Scholar 

  28. Robert J, Morvan VL, Smith D et al (2005) Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54:171–196

    Article  PubMed  Google Scholar 

  29. Stohlmacher J (2005) Pharmacogenetics in gastrointestinal tumors. Onkologie 28:435–440

    Article  PubMed  Google Scholar 

  30. Kweekel DM, Gelderblom H, Guchelaar HJ (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90–105

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine Tongji University Medical School Cancer Institute, Tongji University, No 507 Zhengmin Road, Shanghai, 200433, People’s Republic of China

    Xiaoxia Chen, Hui Sun, Shengxiang Ren, Vikramsingh Kim Curran, Ling Zhang, Songwen Zhou & Caicun Zhou

  2. Department of Lung Cancer and Immunology Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Medical School Cancer Institute, Shanghai, People’s Republic of China

    Jie Zhang

Authors
  1. Xiaoxia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shengxiang Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vikramsingh Kim Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Songwen Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Caicun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caicun Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, X., Sun, H., Ren, S. et al. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol 14, 207–213 (2012). https://doi.org/10.1007/s12094-012-0785-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0785-3

Keywords

Search

Navigation